|Bid||49.99 x 1200|
|Ask||56.97 x 800|
|Day's Range||49.42 - 50.97|
|52 Week Range||25.01 - 173.76|
|Beta (5Y Monthly)||2.67|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2020 - Nov 16, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||75.67|
SAGE earnings call for the period ending June 30, 2020.
Shares of Sage Therapeutics (NASDAQ:SAGE) were flat in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 36.59% over the past year to ($2.08), which beat the estimate of ($2.66).Revenue of $1,089,000 rose by 24.74% from the same period last year, which beat the estimate of $890,000.Guidance Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: Aug 10, 2020View more earnings on SAGETime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/kkevgsu3Recent Stock Performance 52-week high: $174.73Company's 52-week low was at $25.01Price action over last quarter: Up 30.05%Company Description Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.See more from Benzinga * Earnings Scheduled For August 10, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...